375 related articles for article (PubMed ID: 29314658)
1. Comparative assessment of five trials of universal HIV testing and treatment in sub-Saharan Africa.
Perriat D; Balzer L; Hayes R; Lockman S; Walsh F; Ayles H; Floyd S; Havlir D; Kamya M; Lebelonyane R; Mills LA; Okello V; Petersen M; Pillay D; Sabapathy K; Wirth K; Orne-Gliemann J; Dabis F;
J Int AIDS Soc; 2018 Jan; 21(1):. PubMed ID: 29314658
[TBL] [Abstract][Full Text] [Related]
2. What do the Universal Test and Treat trials tell us about the path to HIV epidemic control?
Havlir D; Lockman S; Ayles H; Larmarange J; Chamie G; Gaolathe T; Iwuji C; Fidler S; Kamya M; Floyd S; Moore J; Hayes R; Petersen M; Dabis F;
J Int AIDS Soc; 2020 Feb; 23(2):e25455. PubMed ID: 32091179
[TBL] [Abstract][Full Text] [Related]
3. Achieving the UNAIDS 90-90-90 targets: a comparative analysis of four large community randomised trials delivering universal testing and treatment to reduce HIV transmission in sub-Saharan Africa.
Sabapathy K; Balzer L; Larmarange J; Block L; Floyd S; Iwuji C; Wirth K; Ayles H; Fidler S; Kamya M; Petersen M; Havlir D; Dabis F; Moore J; Hayes R
BMC Public Health; 2022 Dec; 22(1):2333. PubMed ID: 36514036
[TBL] [Abstract][Full Text] [Related]
4. Addressing social issues in a universal HIV test and treat intervention trial (ANRS 12249 TasP) in South Africa: methods for appraisal.
Orne-Gliemann J; Larmarange J; Boyer S; Iwuji C; McGrath N; Bärnighausen T; Zuma T; Dray-Spira R; Spire B; Rochat T; Lert F; Imrie J;
BMC Public Health; 2015 Mar; 15():209. PubMed ID: 25880823
[TBL] [Abstract][Full Text] [Related]
5. HPTN 071 (PopART): rationale and design of a cluster-randomised trial of the population impact of an HIV combination prevention intervention including universal testing and treatment - a study protocol for a cluster randomised trial.
Hayes R; Ayles H; Beyers N; Sabapathy K; Floyd S; Shanaube K; Bock P; Griffith S; Moore A; Watson-Jones D; Fraser C; Vermund SH; Fidler S;
Trials; 2014 Feb; 15():57. PubMed ID: 24524229
[TBL] [Abstract][Full Text] [Related]
6. Cost and cost-effectiveness of a universal HIV testing and treatment intervention in Zambia and South Africa: evidence and projections from the HPTN 071 (PopART) trial.
Thomas R; Probert WJM; Sauter R; Mwenge L; Singh S; Kanema S; Vanqa N; Harper A; Burger R; Cori A; Pickles M; Bell-Mandla N; Yang B; Bwalya J; Phiri M; Shanaube K; Floyd S; Donnell D; Bock P; Ayles H; Fidler S; Hayes RJ; Fraser C; Hauck K;
Lancet Glob Health; 2021 May; 9(5):e668-e680. PubMed ID: 33721566
[TBL] [Abstract][Full Text] [Related]
7. Projected outcomes of universal testing and treatment in a generalised HIV epidemic in Zambia and South Africa (the HPTN 071 [PopART] trial): a modelling study.
Probert WJM; Sauter R; Pickles M; Cori A; Bell-Mandla NF; Bwalya J; Abeler-Dörner L; Bock P; Donnell DJ; Floyd S; Macleod D; Piwowar-Manning E; Skalland T; Shanaube K; Wilson E; Yang B; Ayles H; Fidler S; Hayes RJ; Fraser C;
Lancet HIV; 2022 Nov; 9(11):e771-e780. PubMed ID: 36332654
[TBL] [Abstract][Full Text] [Related]
8. Incidence of self-reported tuberculosis treatment with community-wide universal testing and treatment for HIV and tuberculosis screening in Zambia and South Africa: A planned analysis of the HPTN 071 (PopART) cluster-randomised trial.
Telisinghe L; Floyd S; MacLeod D; Schaap A; Dunbar R; Bwalya J; Bell-Mandla N; Piwowar-Manning E; Donnell D; Shaunaube K; Bock P; Fidler S; Hayes RJ; Ayles HM;
PLoS Med; 2024 May; 21(5):e1004393. PubMed ID: 38820246
[TBL] [Abstract][Full Text] [Related]
9. Predictors of timely linkage-to-ART within universal test and treat in the HPTN 071 (PopART) trial in Zambia and South Africa: findings from a nested case-control study.
Sabapathy K; Mubekapi-Musadaidzwa C; Mulubwa C; Schaap A; Hoddinott G; Stangl A; Floyd S; Ayles H; Fidler S; Hayes R;
J Int AIDS Soc; 2017 Dec; 20(4):. PubMed ID: 29251433
[TBL] [Abstract][Full Text] [Related]
10. Universal test-and-treat in Zambian and South African correctional facilities: a multisite prospective cohort study.
Herce ME; Hoffmann CJ; Fielding K; Topp SM; Hausler H; Chimoyi L; Smith HJ; Chetty-Makkan CM; Mukora R; Tlali M; Olivier AJ; Muyoyeta M; Reid SE; Charalambous S
Lancet HIV; 2020 Dec; 7(12):e807-e816. PubMed ID: 32763152
[TBL] [Abstract][Full Text] [Related]
11. Factors associated with antiretroviral treatment initiation amongst HIV-positive individuals linked to care within a universal test and treat programme: early findings of the ANRS 12249 TasP trial in rural South Africa.
Boyer S; Iwuji C; Gosset A; Protopopescu C; Okesola N; Plazy M; Spire B; Orne-Gliemann J; McGrath N; Pillay D; Dabis F; Larmarange J;
AIDS Care; 2016; 28 Suppl 3(Suppl 3):39-51. PubMed ID: 27421051
[TBL] [Abstract][Full Text] [Related]
12. "It's Not Like Taking Chocolates": Factors Influencing the Feasibility and Sustainability of Universal Test and Treat in Correctional Health Systems in Zambia and South Africa.
Topp SM; Chetty-Makkan CM; Smith HJ; Chimoyi L; Hoffmann CJ; Fielding K; Reid SE; Olivier AJ; Hausler H; Herce ME; Charalambous S
Glob Health Sci Pract; 2019 Jun; 7(2):189-202. PubMed ID: 31249019
[TBL] [Abstract][Full Text] [Related]
13. Costs of implementing universal test and treat in three correctional facilities in South Africa and Zambia.
Mukora R; Smith HJ; Herce ME; Chimoyi L; Hausler H; Fielding KL; Charalambous S; Hoffmann CJ
PLoS One; 2022; 17(8):e0272595. PubMed ID: 36006967
[TBL] [Abstract][Full Text] [Related]
14. Temporal trends of population viral suppression in the context of Universal Test and Treat: the ANRS 12249 TasP trial in rural South Africa.
Larmarange J; Diallo MH; McGrath N; Iwuji C; Plazy M; Thiébaut R; Tanser F; Bärnighausen T; Orne-Gliemann J; Pillay D; Dabis F;
J Int AIDS Soc; 2019 Oct; 22(10):e25402. PubMed ID: 31637821
[TBL] [Abstract][Full Text] [Related]
15. Opportunities and Challenges in HIV Treatment as Prevention Research: Results from the ANRS 12249 Cluster-Randomized Trial and Associated Population Cohort.
Tanser F; Kim HY; Vandormael A; Iwuji C; Bärnighausen T
Curr HIV/AIDS Rep; 2020 Apr; 17(2):97-108. PubMed ID: 32072468
[TBL] [Abstract][Full Text] [Related]
16. Treatment as Prevention: Concepts and Challenges for Reducing HIV Incidence.
Brault MA; Spiegelman D; Hargreaves J; Nash D; Vermund SH
J Acquir Immune Defic Syndr; 2019 Dec; 82 Suppl 2(2):S104-S112. PubMed ID: 31658196
[TBL] [Abstract][Full Text] [Related]
17. Twelve months antiretroviral therapy retention among clients newly enrolled to care and treatment services in Geita Regin, Tanzania: does universal test and treat matter?
Masuke R; Kihaga Y; Mashala M; Ndalio S; Sukari O; Panga O
Pan Afr Med J; 2023; 46():20. PubMed ID: 38035160
[TBL] [Abstract][Full Text] [Related]
18. Pathways for reduction of HIV-related stigma: a model derived from longitudinal qualitative research in Kenya and Uganda.
Camlin CS; Charlebois ED; Getahun M; Akatukwasa C; Atwine F; Itiakorit H; Bakanoma R; Maeri I; Owino L; Onyango A; Chamie G; Clark TD; Cohen CR; Kwarisiima D; Kabami J; Sang N; Kamya MR; Bukusi EA; Petersen ML; V Havlir D
J Int AIDS Soc; 2020 Dec; 23(12):e25647. PubMed ID: 33283986
[TBL] [Abstract][Full Text] [Related]
19. Can combination prevention strategies reduce HIV transmission in generalized epidemic settings in Africa? The HPTN 071 (PopART) study plan in South Africa and Zambia.
Vermund SH; Fidler SJ; Ayles H; Beyers N; Hayes RJ
J Acquir Immune Defic Syndr; 2013 Jul; 63 Suppl 2(0 2):S221-7. PubMed ID: 23764639
[TBL] [Abstract][Full Text] [Related]
20. HIV drug resistance in a community-randomized trial of universal testing and treatment: HPTN 071 (PopART).
Fogel JM; Wilson EA; Piwowar-Manning E; Breaud A; Clarke W; Petropoulos C; Moore A; Fraser C; Kosloff B; Shanaube K; van Zyl G; Scheepers M; Floyd S; Bock P; Ayles H; Fidler S; Hayes R; Donnell D; Eshleman SH;
J Int AIDS Soc; 2022 Jul; 25(7):e25941. PubMed ID: 35775502
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
